title: Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach.
abstract: Six patients with either acceleration or blast crisis of transformed chronic myeloid leukemia (CML) were treated with high-dose interferon alpha in combination with hydroxyurea. All patients responded to the treatment by reversal to stable chronic phase. Two of these patients responded repeatedly during their course of disease. Median time for return to chronic phase was 4 weeks. Adverse side-effects such as nausea, vomiting, hairloss, fever, prolonged cytopenia were not observed.
authors.affiliation: Med. Klinik III, Klinikum Grosshadern, University of Munich, FRG.
authors.forename: U
authors.initials: U
authors.lastname: Jehn
authors.forename: C
authors.initials: C
authors.lastname: Pötscher
authors.forename: V
authors.initials: V
authors.lastname: Heinemann
mesh_terms: D000082:Acetaminophen / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001752:Blast Crisis; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged
chemical_list: D018712:Analgesics, Non-Narcotic; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D003561:Cytarabine; D000082:Acetaminophen; D002066:Busulfan; D008558:Melphalan; D006918:Hydroxyurea